Navigation Links
UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced results from a Phase 1a clinical study of CD-NP, Nile's selective NPR-B agonist being developed for the treatment of heart failure. The results of this study will be included in the Company's presentation today at the BIO Investor Forum in San Francisco, CA.

"The development of a peptide that has natriuretic and renal effects, with relatively little effect on blood pressure, is a potentially important achievement. The results of this trial in healthy volunteers have confirmed some of the hypotheses developed during the pre-clinical studies. We were particularly interested to see a clear, dose dependent increase in cGMP, which suggests the molecule activates the NPR receptors," commented Dr. Barry Massie, Professor of Medicine, University of California, San Francisco, Chief, Cardiology Section, San Francisco VA Hospital, and member of Nile's scientific advisory board.

Study Design

The Phase 1a study was conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of various doses of CD-NP compared to placebo over a four-hour infusion in 22 healthy volunteers. The study evaluated several pharmacodynamic variables which may translate into safety and efficacy in the heart failure population. Nile measured the effect of CD-NP on systemic blood pressure, urinary flow rate, urinary sodium excretion, serum potassium, renal function and cGMP, a secondary messenger of the target receptor and indicator of in-vivo activity.

Study Results

CD-NP was well tolerated with no serious adverse events and all subjects completed the four-hour infusion of placebo, 10, 17.5 or 25 ng/kg/min of CD-NP.

With respect to clinical and biomarker assessments, CD-NP (placebo, 10, 17.5 and 25 ng/kg/min) increased urine flow rate versus baseline (125%, 53%, 30% and 230% average change, respectively), increa
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 According ... by Tumor (Breast, Lung, Prostate) Type (Protein & Genetic ... Drug Discovery, Prognostic) & Geography - Global Forecast to ... expected to reach around 17,689.0 Million USD by 2020 ... of 2015 to 2020. Browse 191 ...
(Date:8/28/2015)... 28, 2015 Research ... addition of the "12th Annual Report and ... report to their offering. The 2015 ... Capacity and Production is the most recent study ... and projected future capacity and production. The report ...
(Date:8/28/2015)... Ill. , Aug. 28, 2015 ... Companies, Inc. (Nasdaq: PDCO ), is now ... previously announced acquisition of Patterson Medical by Madison ... will retain its name for a transition period ... of rehabilitation and sports medicine products.  With the ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... NxStage® Medical , Inc. (Nasdaq: NXTM ... commented on findings of the Chronic Disease Research Group ... frequent, home hemodialysis with the NxStage System One™ are ... with conventional thrice-weekly dialysis, particularly in patients not on ...
...  Amgen (NASDAQ: AMGN ) announced today that ... Research and Development at Amgen will testify at the ... on biosimilars. Miletich will urge members of the FDA ... establish approval standards that advance patient safety and promote ...
Cached Medicine Technology:Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant 2Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant 3Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 2Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 3Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 4Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 5Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 6
(Date:8/28/2015)... ... August 28, 2015 , ... Altima Technologies, ... diagramming network and data center assets and audio-video devices, recently released Visio Stencils ... 5000 Series, HP ProLiant Gen9, EMC VNX Series , Super Micro Computer SuperStorage, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is ... in shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and numbness. ... University of Illinois, and then went on to earn his title of Doctor of ...
(Date:8/28/2015)... ... August 28, 2015 , ... SharkNinja, ... with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® ... Flavor Extraction™ technology, which delivers a variety of sizes and styles while achieving ...
(Date:8/28/2015)... ... 2015 , ... United Benefit Advisors (UBA), the nation’s leading ... its newest Partner Firm. Founded in 1924 and headquartered in Pittsburgh, Pennsylvania, their ... goals. Within the past 10 years, TJS Insurance Group has emerged as one ...
(Date:8/28/2015)... ... August 28, 2015 , ... A complimentary webinar offered by ... & Medicaid Services’ (CMS) proposal to mandate bundled payments through the Comprehensive ... Ready for Game Day: Comprehensive Care for Joint Replacement,” takes place at 12 noon ...
Breaking Medicine News(10 mins):Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3
... -- The risk of being infected with antibiotic-resistant bacteria when ... a new study suggests. Growing concerns about the spread ... programs, but this finding suggests such efforts may not be ... University of Florida College of Medicine collected 240 samples from ...
... Society for Medical Oncology (ESMO), the leading professional ... that medical oncology has been included among the ... recognition of professional qualifications, as announced yesterday by ... years of intense discussion between ESMO, key national ...
... Professor of Molecular & Cell Biology at Boston University ... of Microbiology at Boston University School of Medicine discovered ... of gene expression. The study describing this work titled, ... Premature Transcription Termination," appears in the March 4 issue ...
... research into drugs which could prevent the return of persistent ... major brain tumour charities. The pioneering work in this ... Brain Tumour Research Centre at The University of Nottingham, one ... new research has been jointly funded by the Samantha Dickson ...
... new, rapid blood test that could lead to early ... thousands of people stricken with fungal meningitis, a leading ... closer to market with a recent collaboration between the ... "The ability to quickly identify yeast infection in ...
... Osteoporosis & Osteoarthritis - the most influential European ... Valencia,s award-winning ,Palacio de Congresos, from March 23-26, ... take advantage of lower registration fees. ... bone experts, Learn about key topics in 12 Meet-the-Professor ...
Cached Medicine News:Health News:Risk of Drug-Resistant Staph Infection in Gym Low: Study 2Health News:Novel mechanism for control of gene expression revealed 2Health News:Vital funding for children's brain tumor research 2Health News:University of Nevada, Reno, teams with IMMY to make new life-saving blood test 2Health News:University of Nevada, Reno, teams with IMMY to make new life-saving blood test 3
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... is the same as model ... flat internal baffle across the ... baffle slopes forward, leaving space ... sweep the deck and space ...
... The Benchtop Fume Hood is an ... installations in which a number of fume ... schools, junior colleges and universities. Features include ... polyethylene with rounded inside corners for easy ...
This is the second generation of the famous A/O sliding microtome, manufactured in the United States under the Leica trademark....
Medicine Products: